Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection

Medicine (United States)

Volumn 96, Issue 16, 2017, Pages

  He, Chao ^a   Peng, Wei ^a   Li, Chuan ^a   Wen, Tian Fu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Liver resection; Milan criteria; Prognostic factor; Thymalfasin

Indexed keywords

BILIRUBIN; SORAFENIB; THYMOSIN ALPHA1; VIRUS DNA; ANTINEOPLASTIC AGENT; THYMOSIN;

ABLATION THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROVASCULAR INVASION; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SEPSIS; SMALL HEPATOCELLULAR CARCINOMA; TUMOR INVASION; ADJUVANT CHEMOTHERAPY; AGE; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEX DIFFERENCE; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX FACTORS; THYMOSIN; YOUNG ADULT;

EID: 85018316080     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006606     Document Type: Article

References (27)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
4. Jeng WJ, Lin CC, Chen WT, et al. Adjuvant therapy for hepatocellular carcinoma after curative treatment. Dig Dis 2014;32:747-54.
5. Goldstein AL, Guha A, Zatz MM, et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Nat Acad Sci USA 1972;69:1800-3.
6. Moretti S, Oikonomou V, Garaci E, et al. Thymosin alpha1: burying secrets in the thymus. Expert Opin Biol Ther 2015;15(Suppl 1):S51-8.
7. Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 2009;3:480-9.
8. Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res 2010;40:943-53.
9. Ko CJ, Chien SY, Chou CT, et al. Factors affecting the prognosis of small hepatocellularcarcinoma in Taiwanese patients following hepatic resection. Gastroenterology 2011;25:485-91.
10. Hosaka T, Ikeda K, Kobayashi M, et al. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int 2009;29:736-42.
11. Hong YJ, Kim SH, Choi GH, et al. Long-term outcome after liver resection and clinicopathological features in patients with small hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2011;15:199-205.
12. Baccarani U, Benzoni E, Adani GL, et al. Superiority of transplantation versus resection for the treatment of small hepatocellular carcinoma. Transplant Proc 2007;39:1898-900.
13. Shimozawa N, Hanazaki K. Longterm prognosis after hepatic resection for small hepatocellular carcinoma. J Am Coll Surg 2004;198:356-65.
14. Zhu YB, Xu X, Zheng SS. Association of microvascular invasion with recurrence and prognosis of patients with small hepatocellular carcinoma undergoing liver transplantation. Zhejiang Da Xue Xue Bao Yi Xue Ban 2014;43:658-63.
15. Peng W, Li C, Wen TF, et al. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. J Surg Res 2014; 192:402-8.
16. Zhong J-H, Du XK, Xiang BD, et al. Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial. World J Hepatol 2016;8:957-60.
17. Yang S, Lin Q, Lin W, et al. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol 2016;14:159.
18. Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellar carcinoma patients: a preliminary experience. Hepatogastroenterology 1998;45: 209-15.
19. Cheng SQ, Wu MC, Chen H, et al. Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2004;26:305-7.
20. Shuqun C, Mengchao W, Han C, et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006;53: 249-52.
21. Kuang DM, Zhao Q, Wu Y, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011;54:948-55.
22. Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283-7.
23. Meng W, Bai B, Bai Z, et al. The immunosuppression role of alphafetoprotein in human hepatocellular carcinoma. Discov Med 2016;21: 489-94.
24. Zhao F, Korangy F, Greten TF. Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis 2012;30:477-82.
25. Serafino A, Pierimarchi P, Pica F, et al. Thymosin alpha1 as a stimulatory agent of innate cell-mediated immune response. Ann N Y Acad Sci 2012;1270:13-20.
26. Fan YZ, ChangH, Yu Y, et al. Thymosin alpha1 suppresses proliferation and induces apoptosis in human leukemia cell lines. Peptides 2006;27: 2165-73.
27. Kim BK, Park JY, Kim DY, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008;28:393-401.